Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | CAR-T as a new standard of care in lymphoma

In this video, Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares his insights into the use of chimeric antigen receptor T-cell (CAR-T) therapy as a new standard of care in the treatment of aggressive lymphomas. Dr Jäger draws focus on three studies that have compared CAR-T and autologous stem cell transplant as a second-line therapy in lymphoma: the TRANSFORM study (NCT03575351), the ZUMA-7 study (NCT03391466), and the BELINDA study (NCT03570892). Dr Jäger then explains that the patient population and inclusion criteria will have to be defined more clearly when determining the use of CAR-T as the new standard of care. To conclude, Dr Jäger mentions the emergence of other novel agents, such as bispecific antibodies and CD-19 antibodies, which will also play a role in the future treatment of lymphoma. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Transcript (edited for clarity)

So one of the most exciting questions in the aggressive lymphoma field, is based on the three studies that represented at ASH, the TRANSFORM study, the ZUMA-7 study, and the BELINDA study which all compared CAR-Ts versus autologous stem cell transplant, which is the current standard of care in second-line for these patients. Two of these studies were positive, one was negative, and we will discuss, and are discussing in many, many forums, whether this will now be the new standard...

So one of the most exciting questions in the aggressive lymphoma field, is based on the three studies that represented at ASH, the TRANSFORM study, the ZUMA-7 study, and the BELINDA study which all compared CAR-Ts versus autologous stem cell transplant, which is the current standard of care in second-line for these patients. Two of these studies were positive, one was negative, and we will discuss, and are discussing in many, many forums, whether this will now be the new standard. I personally think the answer is yes.
Then however, we will probably have to define a bit more in detail, which population that will exactly be. It will be patients who qualified previously for autologous transplant and in the studies, the patient groups included were patients who relapsed or were refractory within the first 12 months after the first therapy. And that of course, narrows the population a bit on this high-risk population. And then there were some inclusion criteria which were different between the studies. For instance, if patients with a progressive disease at screening should be included in a second-line treatment with CARs, or if they should rather be treated with other therapies. And also to keep in mind in this regard is that we have a lot of new other agents, particularly bispecifics or CD19 antibodies. And also the coupled antibodies, which will come into this same area. So, I think it will need a lot of discussion between experts, but certainly CARs are one of the new standards in second-line.

Read more...